Psychedelic therapy is anticipated to receive its first federal approval in 2024 and at least one U.S. State will begin issuing licenses to psychedelic therapy service providers in 2023. What do these developments mean for psychoanalytic psychotherapy? Could they catalyze or validate psychoanalytic processes and treatment? Does psychedelic therapy threaten the traditional psychoanalyst, or does it present an opportunity for psychoanalysis to modernize?
This symposium will address these topics and more in a timely dialogue with Professor Robin Carhart-Harris and Dr. Donald Moss, followed by audience Q+A.
Professor Carhart-Harris is Director of the new Psychedelics Division within the translational neuroscience center, Neuroscape, at the University of California, San Francisco.
Dr. Donald Moss is the Chair of the American Psychoanalytic Association’s Program Committee.
Fee structures vary depending on APsA membership and candidacy status. We offer discounted student rates. APsA is committed to expanding the accessibility of psychoanalytic programming. If registration cost presents a barrier to entry, please contact email@example.com and we will accommodate your needs.
For more information and to register, visit our website: www.apsameeting.org
This program will offer 2 Continuing Education Credits.
STATEMENT OF OBJECTIVES
The scientific sessions of the American Psychoanalytic Association’s meetings are intended to bridge the practice gaps in the professional knowledge of attendees by exploring new and recent developments in research, theory, technique, clinical knowledge and by offering opportunities to review essential psychoanalytic knowledge.
After attending the Psychoanalysis and Psychedelics Symposium, attendees should be able to:
1) Describe how psychedelic drugs work on the mind.
2) Discuss how the effect of psychedelic drugs might enhance psychoanalytic treatments.
CONTINUING PROFESSIONAL EDUCATION CREDITS